# argenx SE American (ARGX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $1033.15, market value $64.2 billion.

## Valuation
- **P/E (trailing): 39.4×** (5-yr avg 45.5×, 3-yr avg 45.5×). argenx SE American trades at 39.4× trailing earnings, close to its own five-year average of 45.5×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 26.3×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.49**. A PEG of 0.49 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 12.3×**. Each dollar of revenue is priced at 12.3×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 8.8×**. The shares trade at 8.8× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: 1.1%** (5-yr avg -1.7%). Free cash flow equals 1.1% of the market value, above its five-year average of -1.7%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 2.5%**. The inverse of the P/E: 2.5% of the price is earned each year.

## Profitability
- **Gross margin: 90.0%**. argenx SE American keeps 90.0% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 30.6%**. 30.6% of revenue is left after running the business, an exceptional level.
- **Return on equity: 17.6%**. 17.6% on shareholders' equity is solid.
- **Return on assets: 19.8%**. Each dollar of assets produces 19.8% of profit.

## Growth
- **EPS growth (1 yr): 53.1%**. Earnings per share rose 53.1%.

## Financial health
- **Interest coverage: 418.1×**. Operating profit covers interest 418.1× over, a safe margin.
- **Current ratio: 5.23** (quick 5.23). Current assets cover the next year's liabilities 5.23 times.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. argenx SE American does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (23 analysts). 23 analysts cover argenx SE American; the consensus is strong_buy, with an average price target of $1175.61 (+14% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 40.8%** (YTD 22.9%, 3-mo 15.9%). The shares are up 40.8% over twelve months including dividends.
- **From 52-week high: -3.7%** (56.1% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 61**. An RSI of 61 is neutral.
- **Beta (1 yr): 0.31** (volatility 35%). Beta of 0.31 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ARGX · Page: https://foliofundamentals.com/stocks/argx

Not investment advice.